Pneumology - Original Articles Open access

Concurrent tropical pulmonary eosinophilia and allergic bronchopulmonary aspergillosis in asthma: a prospective observational study from a filariasis-endemic region

Authors

Published
9 November 2026
Issue
Early Access
Section
Pneumology - Original Articles
DOI
10.4081/monaldi.2026.4297

Abstract

Tropical pulmonary eosinophilia (TPE) and allergic bronchopulmonary aspergillosis (ABPA) share cough, wheeze, eosinophilia, and marked immunoglobulin (Ig) E elevation and may coexist in patients with asthma in filariasis-endemic settings. We prospectively characterized this overlap phenotype at a tertiary respiratory center in eastern India. Eligible patients older than 10 years had a documented prior physician diagnosis of asthma and, at presentation, an absolute eosinophil count (AEC) >1000 cells/µL and total IgE >1000 IU/mL; all underwent evaluation for both TPE and ABPA. These laboratory thresholds were study-entry criteria and were not substituted for disease-specific diagnostic definitions. TPE attribution required a compatible clinic-serological profile and a study-defined post-diethylcarbamazine (DEC) haematological response of at least 50% reduction in AEC. For the present analysis, ABPA was classified according to the revised 2024 International Society for Human and Animal Mycology criteria using prospectively collected clinical, immunological, and imaging variables. In TPE-compatible patients, DEC was given before ABPA-directed therapy to preserve interpretation of the eosinophilic response. Among 312 prospectively evaluated patients, 132 met the study definitions for TPE-ABPA overlap, 77 for TPE alone, and 103 for ABPA alone.  In the overlap cohort, mean age was 36.2±15.9 years; median baseline AEC was 6071 cells/µL [interquartile range (IQR) 3793-11,000] and median total IgE was 7641 IU/mL (IQR 4525-13,621). Aspergillus fumigatus-specific IgE and IgG were positive in all 132; the filarial antigen was positive in 128 (97.0%), and there was qualitative filarial IgG in all 132.  The dominant recorded high-resolution computed tomography pattern was normal in 73 (55.3%), while bronchiectasis was recorded in 42 (31.8%). All overlap patients received DEC and fulfilled the study-defined ≥50% AEC response criterion. ABPA-directed treatment comprised systemic corticosteroids alone in 71 (53.8%), itraconazole alone in 41 (31.1%), and both in 20 (15.2%). Concurrent TPE and ABPA should be considered in endemic regions when asthma is accompanied by disproportionate eosinophilia and IgE elevation; recognition of one eosinophilic disorder should not prematurely terminate evaluation for the other.

Keywords

Ethics Approval

Institutional Ethics Committee approval was obtained at Indira Gandhi Institute of Medical Sciences, Patna (approval no. 26/IEC/IGIMS/2021, dated 23 March 2021).

References

  1. Mullerpattan JB, Udwadia ZF, Udwadia FE. Tropical pulmonary eosinophilia - a review. Indian J Med Res 2013;138:295-302.
  2. Ottesen EA, Nutman TB. Tropical pulmonary eosinophilia. Annu Rev Med 1992;43:417-24.
  3. Vijayan VK. Tropical pulmonary eosinophilia: pathogenesis, diagnosis, and management. Curr Opin Pulm Med 2007;13:428-33.
  4. Nutman TB, Vijayan VK, Pinkston P, et al. Tropical pulmonary eosinophilia: analysis of anti-filarial antibody localized to the lung. J Infect Dis 1989;160:1042-50.
  5. O'Bryan L, Pinkston P, Kumaraswami V, et al. Localized eosinophil degranulation mediates disease in tropical pulmonary eosinophilia. Infect Immun 2003;71:1337-42.
  6. Agarwal R, Sehgal IS, Muthu V, et al. Revised ISHAM-ABPA working group clinical practice guidelines for diagnosing, classifying and treating allergic bronchopulmonary aspergillosis/mycoses. Eur Respir J 2024;63:2400061.
  7. Agarwal R, Sehgal IS, Dhooria S, et al. Allergic bronchopulmonary aspergillosis. Indian J Med Res 2020;151:529-49.
  8. Chhabra SK, Dash DJ. Concurrent sensitization to Aspergillus fumigatus in tropical pulmonary eosinophilia. Monaldi Arch Chest Dis 2016;81:736.
  9. Singh M, Peter DK, Gupta S, et al. Allergic bronchopulmonary aspergillosis and tropical pulmonary eosinophilia co-occurrence masquerading as refractory allergic bronchopulmonary aspergillosis. Am J Trop Med Hyg 2024;110:509-11.
  10. Sodhi MK, Aggarwal D, Saini V, Dutta K. Combined allergic bronchopulmonary aspergillosis and tropical pulmonary eosinophilia: a rare co-occurrence. Indian J Chest Dis Allied Sci 2022;64:300-2.
  11. Global Initiative for Asthma. Global strategy for asthma management and prevention. 2026. Available from: https://ginasthma.org/2026-gina-strategy-report/
  12. Shankar M, Ejazi MA, Choubey S, Kumar D. Clinicodemographic profile of tropical pulmonary eosinophilia in a tertiary care institute of Bihar. Indian J Respir Care 2022;11:112-6.
  13. Cooray JH, Ismail MM. Re-examination of the diagnostic criteria for tropical pulmonary eosinophilia. Respir Med 1999;93:655-9.
  14. Fernando SD, Rodrigo C, Rajapakse S. Current evidence on the use of anti-filarial agents in the management of bancroftian filariasis. J Trop Med 2011;2011:175941.
  15. Vijayan VK, Rao KV, Sankaran K, et al. Tropical eosinophilia: clinical and physiological responses to diethylcarbamazine. Respir Med 1991;85:17-20.
  16. Rocha A, Dreyer G, Poindexter RW, Ottesen EA. Syndrome resembling tropical pulmonary eosinophilia but of non-filarial etiology: serological findings with filarial antigens. Trans R Soc Trop Med Hyg 1995;89:573-5.
  17. Rom WN, Vijayan VK, Cornelius MJ, et al. Persistent lower respiratory tract inflammation associated with interstitial lung disease in patients with tropical pulmonary eosinophilia following conventional treatment with diethylcarbamazine. Am Rev Respir Dis 1990;142:1088-92.

Metrics

Citations and online attention from Dimensions, Altmetric and PlumX.

PlumX Metrics

License

Copyright (c) 2026 The Author(s)

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.